FIELD: medicine.
SUBSTANCE: group of inventions relates to ophthalmology, and is intended for the treatment of dry eyes. Method of treating dry eye in a human in need thereof comprising ophthalmically administering an effective amount of a compound, selected from group consisting of: 
and 
, wherein the compound is administered topically, wherein said compound is in an ophthalmologically acceptable carrier. Ophthalmic carrier comprising said compound is also provided.
EFFECT: use of a group of inventions provides the effective treatment of dry eyes.
5 cl, 5 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OPHTHALMIC COMPOSITION | 2012 |
|
RU2625301C2 |
| OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE DAMAGE AND DRY EYE SYMPTOMS | 2019 |
|
RU2806212C2 |
| CYCLOSPORINE DERIVATIVES FOR TREATING OPHTHALMIC AND SKIN DISEASES AND CONDITIONS | 2009 |
|
RU2521358C2 |
| COMPOSITIONS AND METHODS FOR JAK PATH INHIBITION | 2010 |
|
RU2557982C2 |
| OPHTHALMIC MOISTURIZING SOLUTION | 2019 |
|
RU2706703C1 |
| COMPOSITION FOR TREATING DISORDERS OF EXTERNAL SECRETION | 2000 |
|
RU2264816C2 |
| CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS FOR PREPARATION AND METHODS FOR USE THEREOF | 2012 |
|
RU2602062C2 |
| PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING DRY-EYE SYNDROME | 2008 |
|
RU2445098C2 |
| COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF DRY EYES | 2019 |
|
RU2763423C1 |
| LIPID-BASED OPHTHALMIC EMULSION | 2019 |
|
RU2793333C2 |
